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 ABSTRACT 
 
Background 
Indigestible, fermentable carbohydrates are bioactive dietary carbohydrates not 
digested by human enzymes but are fermented into short chain fatty acids and gases 
by colonic bacteria. These carbohydrates display prebiotic effects and may influence 
body mass index (BMI), glucose regulation, blood pressure, and blood cholesterol. 
However, intakes of fermentable carbohydrates have not been explored in the general 
US population and potential metabolic effects have not been well elucidated. The 
purpose of this cross-sectional study was to examine consumption of total fermentable 
carbohydrates and subclasses, oligosaccharides and polyols, in US college students 
(n=359, body fat=25.4±9.3%, 83% female) and potential health differences between 
high and low consumers. 
Methods 
Intake of total fermentable carbohydrates, oligosaccharides, polyols and  their 
subclasses were quantified by the Comprehensive Nutrition Assessment 
Questionnaire. Subjects were classified into lower median (LM) and upper median 
(UM) groups using median split for total grams consumed and grams consumed per 
1000kcal diet (g/1000kcal). Blood glucose and lipids were measured by Cholestech 
LDX®, body fat percent by BODPOD®, and waist circumference and blood pressure 
by standardized instruments and protocols. Median differences in dependent variables 
were analyzed by analysis of variance (ANOVA) and covariance (ANCOVA). 
  
 Results 
Average fermentable carbohydrate intake was 8.0±4.9 grams with approximately even 
amounts coming from oligosaccharides and polyols. The LM for total grams of 
fermentable carbohydrate had higher BMI (24.4±4.6 vs. 23.3±3.7kg/m
2
 respectively; 
p=.022), body fat percent (26.6±9.8 vs. 24.1±8.5%; p=.016), and blood glucose (84±8 
vs. 82±7mg/dL; p=.024) than the respective UM. Using ANCOVA, the LM had higher 
systolic blood pressure than the UM (117±14 vs. 114±14mmHg; p=.028). Findings 
were similar with fermentable carbohydrate expressed as g/1000kcal. Using 
ANCOVA, the LM for OS as g/1000kcal had higher BMI (p=.021) and systolic blood 
pressure (p=.036) than the UM. The LM for polyols as g/1000kcal had higher diastolic 
blood pressure than the UM (p=.045). 
Conclusion 
Fermentable carbohydrate intake was low in this population. However, within this 
range, results suggest higher intake may impact BMI, blood glucose, and blood 
pressure in healthy US college students. Long term and mechanistic studies are needed 
to assess potential relationships, including in at-risk populations. 
 
iv 
 
ACKNOWLEDGMENTS 
 
 I would like to acknowledge my major professor, Dr. Melanson, for all of her 
guidance and encouragement throughout the completion of this thesis. This thesis 
would not have been completed without your expertise and enthusiasm.  
 I would also like to thank my fellow graduate students for their support. Thank 
you, Valerie Calberry and Amy Moore, for always being an exemplary source of 
encouragement and advice. Eric Nelson and Michael MacArthur, thank you for all of 
your spectacular help with data collection and statistical analysis. 
  
v 
 
PREFACE 
This thesis was written to comply with the University of Rhode Island Graduate 
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ABSTRACT 
Background 
Indigestible, fermentable carbohydrates are bioactive dietary carbohydrates not 
digested by human enzymes but are fermented into short chain fatty acids and gases 
by colonic bacteria. These carbohydrates display prebiotic effects and may influence 
body mass index (BMI), glucose regulation, blood pressure, and blood cholesterol. 
However, intakes of fermentable carbohydrates have not been explored in the general 
US population and potential metabolic effects have not been well elucidated. The 
purpose of this cross-sectional study was to examine consumption of total fermentable 
carbohydrates and subclasses, oligosaccharides and polyols, in US college students 
(n=359, body fat=25.4±9.3%, 83% female) and potential health differences between 
high and low consumers. 
Methods 
Intake of total fermentable carbohydrates, oligosaccharides, polyols and  their 
subclasses were quantified by the Comprehensive Nutrition Assessment 
Questionnaire. Subjects were classified into lower median (LM) and upper median 
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(UM) groups using median split for total grams consumed and grams consumed per 
1000kcal diet (g/1000kcal). Blood glucose and lipids were measured by Cholestech 
LDX®, body fat percent by BODPOD®, and waist circumference and blood pressure 
by standardized instruments and protocols. Median differences in dependent variables 
were analyzed by analysis of variance (ANOVA) and covariance (ANCOVA). 
Results 
Average fermentable carbohydrate intake was 8.0±4.9 grams with approximately even 
amounts coming from oligosaccharides and polyols. The LM for total grams of 
fermentable carbohydrate had higher BMI (24.4±4.6 vs. 23.3±3.7kg/m
2
 respectively; 
p=.022), body fat percent (26.6±9.8 vs. 24.1±8.5%; p=.016), and blood glucose (84±8 
vs. 82±7mg/dL; p=.024) than the respective UM. Using ANCOVA, the LM had higher 
systolic blood pressure than the UM (117±14 vs. 114±14mmHg; p=.028). Findings 
were similar with fermentable carbohydrate expressed as g/1000kcal. Using 
ANCOVA, the LM for OS as g/1000kcal had higher BMI (p=.021) and systolic blood 
pressure (p=.036) than the UM. The LM for polyols as g/1000kcal had higher diastolic 
blood pressure than the UM (p=.045). 
Conclusion 
Fermentable carbohydrate intake was low in this population. However, within this 
range, results suggest higher intake may impact BMI, blood glucose, and blood 
pressure in healthy US college students. Long term and mechanistic studies are needed 
to assess potential relationships, including in at-risk populations. 
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INTRODUCTION 
 Obesity has increased in the United States (US) in the past 20 years, with 
approximately 75% of the population age 25-54 years classified as overweight or 
obese [1, 2]. Abdominal obesity is a strong component of metabolic syndrome, a 
group of underlying risk factors which predispose an individual to cardiovascular 
disease (CVD) development [3]. Elevated blood pressure, poor glucose tolerance, and 
atherogenic dsylipidemia are also components of metabolic syndrome related to CVD 
risk [3] as well as risk for hypertension and diabetes [1]. 
 A previous observational study of college students found that 46.9% of 
participating males and 27.2% of females were overweight or obese [4]. Additionally, 
the study found that college adults were at risk for development of metabolic 
syndrome. Obesity prevention measures such as healthy diet and regular physical 
activity have been recommended by the Institute of Medicine in order to combat risk 
of obesity [2, 5]. However, analysis of self reported measures by U.S. college students 
indicated that 52% consumed two or more servings of high saturated fat containing 
foods per day and 36% participated in cardiovascular exercise two or fewer times per 
week [6]. These students exhibited several risk factors for cardiovascular disease 
indicating the need for effective counseling and intervention [6]. 
 The human gut may provide a secondary mechanism for influencing obesity as 
well as blood pressure, glucose tolerance, and dyslipidemia [7-12]. Colonic microflora 
break down substrates otherwise indigestible by the human gastrointestinal system, 
creating new metabolically active products [9-11, 13, 14]. Existing concentrations of 
5 
 
gut bacterial colonies may be modified by ingestion of indigestible, fermentable 
carbohydrates [15-17].  
 Fermentable carbohydrates are carbohydrates consumed in the human diet, not 
digested by the human digestive tract, and ultimately fermented by colonic bacteria 
[18]. This can include resistant starches, non-starch polysaccharides, hemicelluloses, 
pectins, gums, some mono- and disaccharides, polyols, and oligosaccharides (OS) [18-
20]. Of these, non-starch polysaccharides, OS, and some mono- and disaccharides are 
selectively fermented by beneficial colonic bacteria to promote growth and 
colonization of more beneficial bacteria [18].  
 Past research has shown that increased consumption of fermentable 
carbohydrates enhances concentrations of the beneficial gut microflora, bifidobacteria 
[21-23]. In mouse models, changes in dietary carbohydrate intake, specifically 
increasing fermentable carbohydrate intake, are associated with increased 
concentrations of bifidobacteria, a beneficial gut bacteria, and improvement in body 
composition [9, 13]. Additionally, fermentation of carbohydrates in the colon yields 
short chain fatty acid (SCFA) byproducts, which increase circulation of satiety 
hormones [7]. Changes in gut hormone circulation and perceived satiety could result 
in changes in weight and energy balance [7-9]. Satiety, postprandial blood glucose, 
and insulin have improved following short-term consumption of fermentable 
carbohydrates such as oat-bran, barley kernel, or other OS-rich foods [8, 9]. Overall, 
human studies involving supplementation of fermentable carbohydrate have shown 
increases in perceived satiety, decreased energy intake, improved glucose regulation 
and improved lipid profiles [8, 10, 11]. 
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 Current studies focus on the implications of poorly digested, fermentable 
carbohydrates in relation to decreasing adverse gastrointestinal symptoms in subjects 
with irritable bowel syndrome or intestinal bowel disease [14, 19, 24, 25]. In contrast, 
others promote the prebiotic effects exhibited by particular fermentable carbohydrates 
including OS and polyols [20, 26]. However, these are mostly short-term controlled 
laboratory studies. No estimation of fermentable carbohydrate consumption has been 
established in a free-living US population. Furthermore, intakes of subclasses of such 
carbohydrates, including the short-chain polyols and the longer-chain OS, have not 
been explored, especially with regard to their potential impacts on health parameters. 
Given that fermentable carbohydrate consumption may play a role in obesity 
prevention and glucose regulation, further research is needed to fully elucidate the 
potential health effects and average consumption of these carbohydrates [8, 9, 12, 27]. 
 The purpose of this study was to, for the first time to our knowledge, estimate  
intake of fermentable carbohydrates in healthy US college students consuming typical 
western diets in order to observe differences in health parameters between groups of 
high and low consumers. It was hypothesized that individuals with higher intake of 
quantified fermentable carbohydrates (estimated OS and polyols consumed) would 
have lower BMI compared to those consuming less. Secondary hypotheses were that 
individuals consuming more grams of polyols or more grams of OS would have lower 
BMI compared to subjects with low polyol or OS consumption. Exploratory variables 
in this study were blood pressure, blood glucose, and low density lipoprotein 
cholesterol (LDL-C). 
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METHODS 
Research Design: 
 This study was a continuation of the Nutrition Assessment Study, an ongoing 
investigation of health risk factors in college students, which was approved by the 
University of Rhode Island (URI) Institutional Review Board (IRB) (IRB HU1112-
069). This ancillary study of the larger cross-sectional study examined dietary intake 
of indigestible, fermentable carbohydrates and their potential relationships to 
anthropometric, biochemical, and other health related variables. Demographic and 
anthropometric data, collected as a part of the Nutrition Assessment Study, were used 
in statistical analysis along with dietary intake measured via the Comprehensive 
Nutrition Assessment Questionnaire (CNAQ) [28]- an online food frequency 
questionnaire (FFQ). 
Subjects and Recruitment: 
 University of Rhode Island students from an introductory and an advanced 
nutrition course completed anthropometric, dietary, biochemical, and health 
assessments as required course activities, and had the choice of allowing these data to 
be used for research. Course teaching assistants (TAs) informed the students of their 
eligibility to participate, described the study, performed informed consent processes 
and collected signed informed consent forms from those who accepted the invitation 
to participate.  Consenting students in fall 2013, spring 2014, fall 2014, and spring 
2015 were given the opportunity to complete the CNAQ [28] as a dietary assessment 
activity. Data were analyzed from consenting students who completed the CNAQ and 
were apparently free from GI disorders (determined by survey response). Other 
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exclusion criteria included pregnancy and noncompliance with fasting or other data 
collection protocols. All data analyses were conducted on the deidentified data. 
Data Collection Procedure: 
Data Collection Staff-  
 Assessment was conducted by trained teaching assistants and supervised by 
course faculty. Students underwent anthropometric and biochemical assessment at the 
beginning of the semester and completed the CNAQ during regular lab periods. The 
CNAQ was analyzed by the FFQ developers [28] and students were provided with 
dietary analysis results to use for their dietary project.  
Measures- 
 The CNAQ is a 297-item online questionnaire validated in 2010 for use in 
adults, which evaluates intake of 52 nutritional indices [28]. It was designed to analyze 
dietary macronutrients, selected micronutrients, indigestible fermentable 
carbohydrates, starch, glycemic index, and glycemic load [28]. Responses to the 
CNAQ were processed using a food composition database [28]. Fermentable 
carbohydrates estimated by the CNAQ include OS, OS subclasses 
fructooligosaccharide (FOS) and galactooligosaccharide (GOS), polyols, and polyol 
subclasses sorbitol and mannitol. 
 Students completed the CNAQ within 20-40 minutes, but the survey could be 
saved, stopped, and continued over multiple sessions if necessary. Students were 
prompted to evaluate their average intake of foods over a one year duration (responses 
include, but were not limited to “daily”, “weekly”, “monthly”, or “never or rarely”). 
The CNAQ survey page briefly instructed students in documenting conditional items 
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such as those consumed only when in season. Prompts encouraged students to identify 
quantities of foods consumed. It was not possible to submit the FFQ with unanswered 
items. A translation sheet was provided for students to explain differences in 
Australian and American food terminology. Graduate students were present during lab 
time to answer questions. 
 Anthropometric and biochemical measurements were obtained according to 
standardized protocols. Height was measured using a calibrated stadiometer and 
weight using a calibrated scale. Body mass index was calculated from height and 
weight. Body composition measures were obtained after an overnight fast using air 
displacement plethysmography via BODPOD™ (LMI, CA) [29] to obtain body fat 
percentage. Before use, the BODPOD™ instrument was calibrated according to 
manufacturer instruction, subjects were weighed, and height was measured. Blood 
pressure was measured using an electronic sphygmomanometer- the first reading was 
done after the participant had been sitting for at least five minutes, the second and any 
follow-up readings were done at least one minute apart. Biochemical assessment 
consisted of total lipid profile, including LDL-C and blood glucose (mg/dL), measured 
via finger stick using the Alere Cholestech LDX System (Serial No. SNAA122881, 
Alere Inc., Waltham MA). After an overnight fast, blood samples of 40uL were 
collected from students using capillary tubes for analysis. 
 In addition to the above assessments, consenting students completed a brief 
standardized demographic survey at the time of anthropometric assessments. 
Demographic information including age, gender, ethnicity, college major, and school 
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year were collected via the survey. These data were used for descriptive purposes and 
analysis of covariance when necessary. 
Statistical Analysis: 
Sample Size Calculation- 
 Sample size was calculated using G*Power (version 3.1.9.2). Sample size was 
estimated using difference in LDL-C (mmol/L) between a group consuming cereal 
containing oat-beta glucan (LDL-C = 3.59 ± .06mmol/L) and a group consuming 
cereal containing wheat bran (LDL-C = 3.84 ± .05mmol/L) after four weeks of daily 
consumption [30]. Subjects were 154 males and females age 35-70 with a fasting 
LDL-C between 3.0 and 5.0mmol/L. An effect size of 4.527 was calculated. A sample 
size of six was estimated in order to find significance for a power of .8 when alpha 
equals .05. 
Descriptives-  
 Data analysis was conducted using IBM SPSS Statistics, version 22. 
Categorical variables age, gender, ethnicity, major were presented as frequencies and 
percentages. Continuous variables including average fermentable carbohydrate intake, 
biochemical, and anthropometric data were presented as means and standard 
deviations. Normality was also assessed for continuous variables (BMI, body fat 
percent, LDL-C, blood glucose, and blood pressure) using skewness and kurtosis. 
Variables that were not normally distributed were log10 transformed and reassessed 
for normality as previously described. 
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Median Split- 
 Participants who reported consuming less than 500 or more than 5,000kcal per 
day were excluded from analyses [31]. Consumption of OS and polyols quantified by 
the CNAQ were added together in order to quantify fermentable carbohydrate intake. 
Intake of quantified fermentable carbohydrates, oligosaccharides, and polyols were 
quantified per gram (g) and as grams per 1000kcal (g/1000kcal) to control for the 
possibility of increased intake from total consumption. High and low intake of 
quantified fermentable carbohydrates and their subclasses (oligosaccharides and 
polyols) were then determined by median split. Gram intakes of fermentable 
carbohydrate consumed per 1000kcal diet were calculated and high and low intakes 
were determined by median split.  
Analysis of Hypotheses- 
 Analysis of variance (ANOVA) was used to observe differences in BMI 
between high and low intake groups.  Covariates were then determined using 
correlations and Mann-Whitney U tests. For correlations, in the case of normal 
distribution, Pearson chi-squared test was applied. If distribution was not normal, 
Spearman’s rho was used. Analysis of covariance (ANCOVA) was then used to 
observe differences in BMI between high and low intake groups. Exploratory 
dependent variables (blood pressure, blood glucose, and LDL-C) were assessed 
similarly. 
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RESULTS 
Participant Demographics 
 Demographic, anthropometric, biochemical, and nutrient intake data were 
collected from 431 participants. Of these, 36 did not complete the CNAQ. In some 
cases, students enrolled in both the introductory and senior course and data were 
collected twice. For these cases, the most complete data set was used for each 
participant. Participants who reported consuming less than 500 or more than 5,000kcal 
per day were excluded from analyses (n = 26) [31]. One participant was excluded from 
the study due to pregnancy. Two participants were excluded from blood pressure 
analyses and two from blood panel analyses due to non-compliance with data 
collection protocols.  
 Data from 359 participants were used in analysis. Ninety-three percent of the 
population was between 18 and 24 years old (Table 2). The participant population was 
83% female, 84% Caucasian/white, 40% freshman, and 28% were seniors or higher 
education. Average participant BMI was 23.9 ± 4.3 kg/m
2
 and average body fat 
percentage was 25.4 ± 9.3%. 
Average Intakes 
 Mean quantified fermentable carbohydrate intake was 8.0±4.9g and 3.4±1.4 
g/1000kcal (Table 3). Mean oligosaccharide intake was 4.0±2.5g and 1.7±0.7 
g/1000kcal. Mean polyol intake was 4.0±3.1g and 1.7±0.7 g/1000kcal. Average 
intakes for subclasses of oligosaccharides and polyols are listed in Table 3. 
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Determination of Covariates 
 Mann-Whitney U tests between median groups initially identified student 
gender, enrollment in either the introductory or senior course, and whether or not 
students majored in nutrition as potential covariates (p<.05). Using correlations, fiber 
was identified as a covariate (p<.000) for total fermentable carbohydrates, 
oligossacharides, and polyols consumed in total grams or g/1000kcal. When using 
ANCOVA to examine differences in mean intake, enrollment in the introductory or 
senior course was not significantly different between groups. Independent variables 
discussed below were run in ANCOVA with gender, major, and fiber as covariates. 
Differences between High and Low Fermentable Carbohydrate Intakes 
Gram intake- 
 The mean lower median (LM) intake of quantified fermentable carbohydrates 
was 4.9±1.6g and the mean upper median (UM) intake was 11.8±4.9g (Table 4). 
Using analysis of variance, the LM had higher BMI (24.4±4.6 vs. 23.3±3.7 kg/m
2
 
respectively; p=.022), body fat percent (26.6±9.8 vs. 24.1±8.5%; p=.016), and blood 
glucose (84±8 vs. 82±7 mg/dL; p=.024) than the respective UM groups. After using 
ANCOVA to adjust for gender, major, and fiber intake, systolic blood pressure was 
higher in the LM than the UM (117±14 vs. 114±14 mmHg respectively; p=.028). 
Gram/1000kcal intake- 
 Mean LM intake of quantified fermentable carbohydrates was 2.4±0.6 
g/1000kcal and mean UM intake was 4.4±1.2 g/1000kcal (Table 4). Using analysis of 
variance, the LM had higher BMI (24.5±4.6 vs. 23.3±3.8 kg/m
2
; p=.009), systolic 
blood pressure (118±15 vs. 113±13 mmHg; p=.001), and diastolic blood pressure 
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(75±9 vs. 72±9 mmHg; p=.004) than the respective UM groups. After using 
ANCOVA to adjust for gender, major, and fiber intake, differences between LM and 
UM groups remained significant only for systolic blood pressure (p=.027) and 
diastolic blood pressure (p=.020). 
Differences between High and Low Oligosaccharide Intakes 
Gram intake- 
 Mean LM intake of oligosaccharides was 2.3±0.7g and UM intake was 
5.8±2.5g (Table 5). No differences between groups were statistically significant in 
ANOVA or ANCOVA. 
Gram/1000kcal intake- 
 Mean LM intake of oligosaccharides was 1.2±0.3 g/1000kcal and UM intake 
was 2.2±0.6 g/1000kcal (Table 5). Using analysis of variance, the LM had higher BMI 
(24.7±4.6 vs. 23.1±3.8 kg/m
2
; p=.001), systolic blood pressure (118±15 vs. 113±14 
mmHg; p=.002), and diastolic blood pressure (75±9 vs. 73±9 mmHg; p=.038) than the 
respective UM groups. After using ANCOVA to adjust for gender, major, and fiber 
intake, differences between LM and UM remained significant for BMI (p=.021) and 
systolic blood pressure (p=.036). 
Differences between High and Low Polyol Intakes 
Gram intake- 
 Mean LM intake of polyols was 2.0±0.8g and UM intake was 6.0±3.2g (Table 
6). Using analysis of variance, blood glucose was higher in the LM than the UM (84±7 
and 82±7 mg/dL respectively; p=.018). After using ANCOVA to adjust for gender, 
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major, and fiber intake, systolic blood pressure was higher in the LM than the UM 
(117±14 and 115±14 mmHg respectively; p=.019). 
Gram/1000kcal intake- 
 Mean LM intake of polyols was 1.0±0.3 g/1000kcal and UM intake was 
2.5±1.0 g/1000kcal (Table 6). Using analysis of variance, the LM had higher blood 
glucose (84±7 vs. 82±8 mmHg; p=.020), systolic blood pressure (117±14 vs. 114±15 
mmHg ; p=.045), and diastolic blood pressure (75±9 vs. 72±9 mmHg; p=.018) than 
the respective UM groups. After using ANCOVA to adjust for gender, major, and 
fiber intake, diastolic blood pressure remained significantly different between LM and 
UM groups (p=.045). 
 
DISCUSSION 
 This study is the first to estimate habitual intake of fermentable carbohydrates 
and fermentable carbohydrate subclasses in a large sample of 359 US college students. 
To our knowledge, this is the first study to observe differences in body mass and blood 
pressure between groups with high and low fermentable carbohydrate intake. This is 
also the first study to use the CNAQ for applied research purposes. 
 Participants consuming more quantified fermentable carbohydrates as 
measured by the CNAQ displayed a lower average BMI using ANOVA, but this did 
not remain significant when applied in ANCOVA. Participants consuming more 
oligosaccharides g/1000kcal displayed a lower average BMI using both ANOVA and 
after correcting for confounding variables with ANCOVA. Potential mechanisms 
leading to differences in BMI could be related to an increase in circulation of satiety 
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hormones after consumption of fermentable carbohydrate such as OS [8, 27]. The 
SCFA produced during fermentation may increase circulation of satiety hormones [7]. 
Intake of single meals that included fermentable carbohydrate have shown decreased 
plasma ghrelin and decreased energy intake at subsequent meals compared to meals 
consumed with little fermentable carbohydrate [8]. Additionally, consumption of 50 
grams indigestible carbohydrate at an evening meal resulted in increased perceived 
satiety ratings in healthy subjects [27]. Similar increases in satiety and decreases in 
energy intake were seen in healthy adults age 21-39 of normal BMI after 2 weeks of 
supplementation with 16g indigestible carbohydrate as oligofructose [32]. The current 
study did not measure satiety or plasma levels of satiety hormones, but this should be 
pursued in future work to determine if observed differences in BMI might be 
explained through such satiety-related mechanisms. 
 Systolic and diastolic blood pressures were lower with higher intakes of 
quantified fermentable carbohydrates as well as their subclasses, oligosaccharides and 
polyols. Few clinical trials have investigated the effects of fermentable carbohydrates 
on blood pressure. Potential mechanisms responsible for the differences observed 
pertain to regulation of angiotensin-converting enzyme (ACE) activity, glucose 
tolerance, and systemic inflammation [33, 34]. These mechanisms have been 
investigated in studies using probiotic supplementation and foods fermented with 
probiotics [33, 35, 36], but need to be explored with prebiotics such as fermentable 
carbohydrate.  
 While, prebiotic substances such as OS can be used to improve intestinal 
microbiota concentrations by acting as a substrate for existing bacteria [23], probiotics 
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are live cultures that can achieve the same goal by directly providing beneficial 
bacteria through the diet [33]. Probiotic supplementation in a controlled, randomized 
double-blind study has been associated with a 6.7mmHg decrease in systolic blood 
pressure after 21 weeks in hypertensive individuals in a study by Seppo et al. [36]. 
This association was also seen in a four week randomized, placebo-controlled double-
blind study by Aihara et al. [35]. These observations could be partially due an ACE-
inhibitory activity of fermentation byproducts [37], however more investigation is still 
necessary. Fermented dairy products have exhibited increased ACE-inhibitory activity 
[38, 39]. Increased ACE activity can increase blood pressure by stimulating the 
production of a vasoconstrictor and degradation of a vasodilator [40, 41], therefore, 
decreased ACE activity could inhibit increases in blood pressure. 
 Soluble fibers can exhibit a prebiotic effect  similar to fermentable 
carbohydrates such as OS and polyols [20]. The observed differences in blood 
pressure between groups in this study are consistent with past research associating 
total dietary or soluble fiber with decreases in blood pressure [42-44]. A meta-analysis 
of randomized controlled trials found a negative association between total dietary fiber 
(soluble and insoluble) intake and blood pressure [44]. Both systolic and diastolic 
blood pressures were lowered more in hypertensive populations than in normotensive. 
Sex and BMI did not affect these differences. A previous study in normotensive 
subjects found small decreases in blood pressure after 12 weeks of psyllium fiber (a 
source of viscous, soluble fiber fermented similarly in the colon) supplementation, 
however this was not significantly different from the control group [43]. In the current 
study, differences in blood pressure of the observed population groups existed even 
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though the majority of participants were not hypertensive. The potential mechanism 
by which insoluble fiber or fermentable carbohydrate intake impacts blood pressure is 
not fully understood and is still being investigated [43]. Arterial stiffness has been 
associated with increases in systolic and diastolic blood pressure [45] and is a major 
risk factor for cardiovascular disease [45, 46]. Dietary fiber can impact insulin 
regulation and vascular function which may both alter blood pressure [42]. 
 In this study, there was a 2mg/dL difference in fasting blood glucose between 
groups of high and low intake for total fermentable carbohydrates and for polyols. 
However, these differences were not significantly different when applied in 
ANCOVA. Increased fiber intake is associated with increased insulin regulation and 
can slow absorption of complex carbohydrates, which may impact blood glucose 
regulation [42]. Previous studies have observed lower postprandial blood glucose 
peaks and total glucose circulation following meals containing fermentable 
carbohydrate [8, 27]. 
 In this study, no observed differences in LDL-C were observed. It has been 
established that water soluble fibers bind to and interfere with resorption of bile acids 
[47], however the mechanistic role of SCFA byproducts on cholesterol lowering 
effects of fermentable carbohydrate are still being explored [7, 48-51]. Both SCFA 
and fermentable sugar beet fiber containing diets have shown lowered plasma 
cholesterol compared to a fiber-free control diet in rats [49]. However, one study in 12 
men (average age 23 years) did not show significant change in blood lipid profiles 
after 3 weeks of 15g inulin, FOS or GOS supplementation [52]. This could potentially 
be due to the study population being apparently healthy and non-diabetic, or because 
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baseline lipid values were low [52]. The population examined in the present study was 
also apparently healthy. 
 Study limitations included a mainly female, Caucasian population, so future 
work should include more males and a more racial-ethnic diversity. As mentioned 
previously, it included only oligosaccharides and polyols as fermentable 
carbohydrates. Although additional work is needed on other types of fermentable 
carbohydrates, such as resistant starches and soluble fibers, focusing on 
oligosaccharides and polyols can also be seen as a study strength since, to date, so 
little human work has been published on these. Additionally, the observed intakes of 
fermentable carbohydrates were low and differences between high and low median 
intake groups were relatively small, so increased intakes may make more of a 
difference. To our knowledge this research provides the first quantification of 
oligosaccharide and polyol intake in a free-living US population and has suggested 
some potential health benefits despite low consumption. This is the first time this has 
been documented outside controlled laboratory intervention studies and has tested the 
largest number of subjects to date for these hypotheses. This study was also the first to 
observe higher BMI and blood pressure in a group of low fermentable carbohydrate 
consumers compared to high consumers. 
 Few instruments are available to quantify intakes of fermentable carbohydrates 
and their subclasses in large populations. No US-validated FFQ or nutrient database 
provides all of these carbohydrate subclasses, so the Australian-validated CNAQ was 
used in this study [28]. Intakes of fermentable carbohydrates were found to be low, as 
indicated by the CNAQ. However, the amounts consumed in this study were high 
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enough to elicit differences in some health indices, even within this apparently healthy 
population. 
 The results of this study found significantly lower BMI and systolic blood 
pressure in participants consuming more grams or grams per 1000 kcal of fermentable 
carbohydrates and oligosaccharides. Subjects with higher polyol intakes also showed 
potentially lower systolic blood pressure and fasting blood glucose. Despite some 
differences of only a few points, it is important to note that a small change in health 
parameters can translate to decreased health risk. For example, difference of 2mmHg, 
as observed in this study, can significantly decrease mortality from stroke and CVD 
[53]. Observations in this study were made using healthy, young adult participants, so 
may not represent changes seen in at-risk or older populations 
  As this study was cross-sectional no causality can be inferred. Further large 
scale, longitudinal studies and intervention studies are necessary to understand the 
potential health impacts of fermentable carbohydrates and their subclasses. 
Additionally, further investigation into the mechanisms of action leading to observed 
differences is necessary to elucidate the function and potential uses of fermentable 
carbohydrates. Longitudinal and mechanistic information could be used when further 
researching fermentable carbohydrate consumption and its action in at risk 
populations. 
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Table 1. Participants 
Total Participant n 431 
Excluded Participants: n 
No FFQ 36 
Repeat participants* 7 
Pregnant 1 
Error in FFQ results 2 
<500 kcal/day reported 2 
>5000kcal/ day reported 24 
Total Excluded 72 
Final n 359 
* For repeat participants, the most 
complete data set was used for analysis 
 
Table 2. Participant Demographics (n =359) 
  n % 
Age 18-24 years 334 93% 
  >24 years 25 7% 
Gender Male 62 17% 
  Female 297 83% 
Ethnicity Caucasian 302 84% 
  African American 4 1% 
  Hispanic/Latino 17 5% 
  Asian 14 4% 
  Other 22 6% 
School 
Year 
Freshman 142 40% 
Sophomore 63 17% 
  Junior 34 9% 
  Senior or higher edu. 99 28% 
  Non-response 21 6% 
Major Nutrition only* 196 55% 
    Mean Std dev 
BMI (kg/m
2
) 23.9 4.3 
Body Fat (%) 25.4 9.3 
BMI=body mass index 
*Participants who declared themselves as nutrition 
majors with no other additional major. 
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Table 3. Average Fermentable Carbohydrate Intake (n = 359) 
  Min Max Mean ± std dev 
Total Fermentable CHO (g) 1.1 39.2 8.0 ± 4.9 
Total Fermentable CHO 
(g/1000kcal) 
0.7 10.7 3.4 ± 1.4 
OS (g) 0.7 20.1 4.0 ± 2.5 
OS (g/1000kcal) 0.3 5.2 1.7 ± 0.7 
FOS (g) 0.4 9.4 2.6 ± 1.6 
FOS (g/1000kcal) 0.2 4.4 1.1 ± 0.4 
GOS (g) 0.1 11.5 1.4 ± 1.3 
GOS (g/1000kcal) 0.1 2.6 0.6 ± 0.4 
Polyols (g) 0.4 26.4 4.0 ± 3.1 
Polyols (g/1000kcal) 0.2 7.1 1.7 ± 1.1 
Sorbitol (g) 0.2 22.9 3.0 ± 2.6 
Sorbitol (g/1000kcal) 0.1 6.3 1.3 ± 0.9 
Mannitol (g) 0.0 6.9 1.0 ± 0.9 
Mannitol (g/1000kcal) 0.0 3.8 0.4 ± 0.4 
CHO=carbohydrate; OS=oligosaccharide; FOS=fructooligosaccharide; 
GOS=galactooligosaccharide 
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Table 4. Differences in High vs Low Fermentable Carbohydrate Intake 
  
n mean ± std dev significance (p) 
LM / UM LM UM ANOVA ANCOVA 
IFCHO (g) 197/162 4.9 ± 1.6 11.8 ± 4.9     
BMI (kg/m2) 166/130 24.4 ± 4.6 23.3 ± 3.7 .022* .109 
Body Fat (%) 177/147 26.6 ± 9.8 24.1 ± 8.5 .016* .256 
LDL-C (mg/dL) 166/139 84 ± 24 86 ± 32 .799 .204 
GLC (mg/dL) 178/150 84 ± 8 82 ± 7 .024* .476 
SBP (mmHg) 179/151 117 ± 14 114 ± 14 .177 .028* 
DBP (mmHg) 179/151 74 ± 9 73 ± 8 .466 .445 
IFCHO 
(g/1000kcal) 
179/180 2.4 ± 0.6 4.4 ± 1.2     
BMI (kg/m2) 147/149 24.5 ± 4.6 23.3 ± 3.8 .009* .110 
Body Fat (%) 160/164 25.5 ± 9.7 25.4 ± 9.0 .881 .342 
LDL-C (mg/dL) 150/155 84 ± 25 86 ± 31 .557 .254 
GLC (mg/dL) 161/167 84 ± 7 82 ± 7 .127 .798 
SBP (mmHg) 159/171 118 ± 15 113 ± 13 .001** .027* 
DBP (mmHg) 159/171 75 ± 9 72 ± 9 .004** .020* 
IFCHO=indigestible, fermentable carbohydrate; BMI=body mass index; LDL-C= 
low density lipoprotein cholesterol; GLC=blood glucose; SBP=systolic blood 
pressure; DBP=diastolic blood pressure; LM=lower median; UM=upper median 
*  significance p<.05 
**  significance p<.01 
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Table 5. Differences in High vs Low Oligosaccharide Intake 
  n mean ± std dev significance (p) 
  LM / UM LM UM ANOVA ANCOVA 
OS (g) 180/179 2.3 ± 0.7 5.8 ± 2.5 
  
BMI (kg/m2) 153/143 24.2 ± 4.2 23.6 ± 4.3 .228 .734 
Body Fat (%) 162/162 26.4 ± 9.3 24.5 ± 9.3 .077 .660 
LDL-C (mg/dL) 150/155 87 ± 26 83 ± 31 .135 .274 
GLC (mg/dL) 163/165 83 ± 8 83 ± 7 .457 .355 
SBP (mmHg) 164/166 116 ± 14 115 ± 15 .856 .655 
DBP (mmHg) 164/166 73 ± 9 74 ± 9 .379 .206 
OS 
(g/1000kcal) 
179/180 1.2 ± 0.3 2.2 ± 0.6 
  
BMI (kg/m2) 148/148 24.7 ± 4.6 23.1 ± 3.8 .001** .021* 
Body Fat (%) 161/163 26.2 ± 9.9 24.7 ± 8.7 .155 .146 
LDL-C (mg/dL) 151/154 86 ± 27 84 ± 30 .512 .789 
GLC (mg/dL) 162/166 84 ± 7 82 ± 7 .160 .840 
SBP (mmHg) 161/169 118 ± 15 113 ± 14 .002** .036* 
DBP (mmHg) 161/169 75 ± 9 73 ± 9 .038* .097 
OS=oligosaccharide; BMI=body mass index; LDL-C= low density lipoprotein 
cholesterol; GLC=blood glucose; SBP=systolic blood pressure; DBP=diastolic blood 
pressure; LM=lower median; UM=upper median 
* significance p<.05 
** significance p<.01 
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Table 6. Differences in High vs. Low Polyol Intake 
  n mean ± std dev significance (p) 
  LM / UM LM UM ANOVA ANCOVA 
Polyol (g) 181/178 2.0 ± 0.8 6.0 ± 3.2 
  
BMI (kg/m2) 150/146 24.2 ± 4.6 23.6 ± 3.9 .193 .565 
Body Fat (%) 162/162 26.4 ± 10.1 24.5 ± 8.4 .063 .888 
LDL-C (mg/dL) 155/150 84 ± 25 86 ± 32 .685 .275 
GLC (mg/dL) 163/165 84 ± 7 82 ± 7 .008** .108 
SBP (mmHg) 164/166 117 ± 14 115 ± 14 .213 .016* 
DBP (mmHg) 164/166 74 ± 9 73 ± 9 .579 .611 
Polyol 
(g/1000kcal) 
180/179 1.0 ± 0.3 2.5 ± 1.0 
  
BMI (kg/m2) 150/146 24.2 ± 4.5 23.6 ± 4.0 .218 .746 
Body Fat (%) 164/160 25.4 ± 10.0 25.5 ± 8.6 .895 .211 
LDL-C (mg/dL) 156/149 83 ± 24 87 ± 32 .201 .098 
GLC (mg/dL) 165/163 84 ± 7 82 ± 8 .020* .132 
SBP (mmHg) 164/166 117 ± 14 114 ± 15 .045* .080 
DBP (mmHg) 164/166 75 ± 9 72 ± 9 .018* .045* 
 BMI=body mass index; LDL-C= low density lipoprotein cholesterol; GLC=blood 
glucose; SBP=systolic blood pressure; DBP=diastolic blood pressure; LM=lower 
median; UM=upper median 
* significance p<.05 
** significance p<.01 
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APPENDIX 1: REVIEW OF LITERATURE 
 
Indigestible Fermentable Carbohydrates 
Fermentable Carbohydrates Defined- 
 Indigestible, fermentable carbohydrates are carbohydrates consumed in the 
human diet, not digested by the human digestive tract, and ultimately fermented by 
colonic bacteria [18]. This can include indigestible oligosaccharides (OS), polyols, 
resistant starches, non-starch polysaccharides, hemicelluloses, pectins, gums, and plant 
cell wall polysaccharides [18]. Of the total fermentable carbohydrate consumed daily, 
approximately 8-40 grams are consumed as resistant starch, 8-18 grams as non-starch 
polysaccharides, 2-10 grams as unabsorbed sugars, and 2-8 grams as OS [21, 54].  
 Fermentation of particular types of these carbohydrates selectively fermented 
to promote the growth of beneficial bifidobacteria and lactobacilli in the colon [15, 17, 
55, 56]. Resistant starch as well as non-starch polysaccharides are varieties of 
fermentable carbohydrates that are not selectively fermented and can therefore 
promote growth of beneficial as well as pathogenic bacteria [11, 13]. While resistant 
starch makes up the majority of colonically fermented carbohydrate it is not yet 
quantifiable in the free-living human diet because resistant starch availability and 
digestibility can be altered by numerous environmental factors such as age of food 
items, cooking method, cooling, and reheating [57]. Conversely, while OS and polyols 
are typically consumed in smaller amounts, they are quantifiable and are selectively 
fermented [21, 23, 28, 58, 59]. 
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Oligosaccharides- 
 Oligosaccharides are carbohydrate chains consisting of 2-10 monosaccharide 
units linked by β-glycosidic bonds, which cannot be broken down by human 
gastrointestinal enzymes [60]. As these bonds are not digested or absorbed in the small 
intestine, OS pass to the colon.  
 Two subtypes of OS are galactooligosaccharides (GOS) and 
fructooligosaccharides (FOS). Galactooligosaccharides are monosaccharide chains 
found in soy, beans, peas, and lentils [61], but they can also be commercially produced 
from lactose [62]. These carbohydrates are more readily used by bifidobacteria than 
any other OS [56]. Fructooligosaccharides are monosaccharide chains present in 
grains and pastas, fruits, scallions, onions, artichoke, and garlic [63, 64].  
 Oligosaccharides escape hydrolysis by mammalian enzymes due to the β (2-1) 
links that connect the monosaccharide units [55]. Bifidobacteria produce the 
intracellular enzymes, B-fructofuranosidase, B-galactosidase, and other enzymes that 
hydrolyze β (2-1) links and α (1-2) links found in OS [23, 65]. Because bifidobacteria 
produce enzymes capable of OS breakdown, growth of bifidobacterial colonies can be 
selectively stimulated [55]. 
Polyols- 
 Along with fibers and resistant starches, polyols or “sugar alcohols” are the 
most prevalent low digestible carbohydrates found in the US food supply [66]. They 
are found naturally in some fruits, mushrooms, and cauliflower, but can also be 
synthesized for addition to food products [66, 67]. Polyols are the reduced forms of 
different mono- and disaccharides [66]. Two polyols, sorbitol and mannitol, are 
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hydrogenated forms of their monosaccharide counterparts, glucose and mannose 
respectively [66]. While some polyols can be absorbed in the small intestine, 
hydrogenated monosaccharides and dissacharides are more resistant to enzymatic 
activity in the human intestine, resulting in passage to the large intestine [66]. 
Different polyols range in sweetness from 40-100% that of sucrose [67], but are lower 
in caloric density because of their low digestibility making them viable sugar 
substitutes [66, 68, 69]. Large amounts of polyols in the colon may result in diarrhea 
due to their rapid fermentation increasing luminal osmolarity [66].   
FODMAP Diets- 
 Current research focuses on the implications of fermentable carbohydrates in 
relation to adverse symptoms of irritable bowel syndrome or intestinal bowel disease 
[14, 19, 24, 25]. This is achieved by reducing particular types of fermentable oligo- di- 
monosaccharides, and polyols in the diet, often referred to as the low FODMAP diet. 
Reduced FODMAP intake decreases the amount of indigestible, fermentable 
carbohydrate that passes undigested through the small intestine and into the colon as 
substrate for bacterial fermentation. This decreases the osmotic effects experienced in 
the colon and can decrease adverse symptoms experienced by individuals with 
gastrointestinal disorders. 
Indigestible Fermentable Carbohydrates, the Microbiome, and Health 
Prebiotics- 
 Some fibers and certain types of fermentable carbohydrates exhibit prebiotic 
properties [20, 26]. Prebiotics are a specific type of colonic carbohydrate. They are 
food substances consumed or added to the diet that selectively promote the growth of 
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certain types of pre-existing bacterial colonies [18]. Like general colonic 
carbohydrates, they escape human digestion and travel to the colon, but not all bacteria 
present in the colon are equally able to ferment and utilize these carbohydrates. 
Prebiotics promote growth of beneficial bacteria only [18].  Compounds including 
FOS, soybean OS, raffinose, and stachyose have been established as prebiotics [18, 
70]. 
The Microbiome- 
 Bacteroides and firmicutes are the predominant types of bacteria found in the 
microbiome [26, 71]. Lactobacilli, an order of firmicutes, as well as bifidobacterium, a 
bacteria found in lesser concentrations, are known to be the most beneficial types of 
gut microbes [72]. Bifidobacteria is thought to be one of the most beneficial types of 
bacteria due to its ability to inhibit growth of pathogenic bacteria, antibacterial 
properties, and immunomodulatory potential [18, 22, 73]. 
 Ratios of microbiome bacterial concentrations vary on an individual basis due 
to a variety of modifiable and unmodifiable factors. In mice, genetics plays a 
prominent role in determining gut bacteria ratios [74]. Bifidobacteria concentrations 
are lower in overweight subjects compared to lean subjects [9, 11]. As previously 
discussed, alterations in diet can also alter concentrations of gut bacteria [11, 13, 71]. 
 Human studies on healthy subjects and those at metabolic risk have shown 
consumption of fermentable carbohydrate can change bifidobacteria concentrations 
and improve metabolic risk factors such as glucose regulation and lipid profiles [8, 10, 
11]. In general, existing concentrations of gut bacterial colonies remain stable over 
time, but can be modified by ingestion of indigestible, fermentable carbohydrates [15-
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17]. In mouse models, changes in dietary carbohydrate and fat are associated with 
alteration of gut bacteria ratios and changes in body composition indicating that gut 
microflora modulation may play a role in management of weight and energy balance 
[13].  
 Due to high variation in bacteria concentrations between individuals, variable 
responses to prebiotic supplementation have been documented [17]. Greater 
promotion of beneficial bacterial growth and improved intestinal function are seen in 
those with low initial bifidobacteria [17]. Humans who consumed 6.6g FOS and 3.4g 
partially hydrolyzed guar gum from biscuits exhibited significantly higher 
concentrations of beneficial colonic bacteria after 21 days [17]. Additionally, subjects 
who have initially low concentrations of bifidobacteria are likely to benefit more from 
fermentable carbohydrate consumption. Tuohy et al. [17] found that individuals who 
had a lower initial concentration of bifidobacteria had greater increases in 
concentration after 21 days of fermentable carbohydrate supplementation. 
Health Applications- 
 Including the beneficial bacteria discussed, the more than 500 types of 
microflora in the human gut provide a secondary mechanism for energy balance, 
glucose tolerance, satiety hormone regulation, and altering disease risk by breaking 
down substrates otherwise indigestible by the human gastrointestinal system [7, 9-11, 
13, 14]. Fermentation of indigestible carbohydrates by these bacteria produces 
hydrogen gas, carbon dioxide, methane, and short chain fatty acids [7]. Short chain 
fatty acid products of bacterial fermentation may improve blood lipid profile and serve 
to decrease intestinal pH, which improves absorption of minerals [75]. Due to the 
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large potential impact of colonic bacterial colonies, understanding environmental 
effects on the microbiome and their resultant effects on the human body is a necessity. 
Products and Effects of Dietary Fermentable Carbohydrate Metabolism 
 It is known that particular fermentable carbohydrate, including polyols, 
fructans, and oligosaccharides, have health benefits and prebiotic uses [19, 20, 71]. 
Increased consumption of fermentable carbohydrate has shown lower low density 
lipoprotein cholesterol (LDL-C) [12, 76] and also improve fasting and postprandial 
glucose regulation [8, 11, 13]. Studies have demonstrated lower caloric intake and 
decreased body weight post-intervention with increased consumption of fermentable 
carbohydrates [8, 76]. However, studies on these carbohydrates have been relatively 
small (n<100) and most have not assessed fermentable carbohydrate intake in 
populations without complicating factors (ex. hypercholesterolemia, irritable bowel 
syndrome, diabetes). 
Byproducts of Bacterial Fermentation- 
 Consumption and colonic fermentation of indigestible carbohydrates produces 
short chain fatty acids (SCFA), hydrogen gas, and carbon dioxide [7]. These SCFA 
products may play physiological roles in colon health, satiety, and cholesterol 
metabolism [7, 48, 77]. The human host is able to absorb and utilize SCFA in body 
tissues [78]. Additionally, increased concentration of SCFA can decrease colonic pH 
and create an acidic environment that discourages growth of pathogenic microbes and 
promotes growth of beneficial bacteria [77]. Different SCFA products  may influence 
lipid and cholesterol metabolism by binding of bile salts and other unidentified 
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impacts on the cholesterol biosynthesis pathway actuated or inhibited by SCFA  [7, 
48-51]. 
 Because of the extensive diversity of its microbiota, the human colon has a 
large capacity to produce various metabolites, both beneficial and harmful [7]. 
Although the complete pathogenesis is unclear, colonic microbiota dysfunction has 
been associated with diabetes, colon cancer, Inflammatory Bowel Disease (IBD), 
Irritable Bowel Syndrome (IBS), and changes in immune response [79]. Specific 
products of microbial fermentation include the SCFAs: acetate, propionate, and 
butyrate [80]. Acetate is typically produced in the largest quantity [80]. 
 The SCFAs produced in the colon are either used by the colonocytes or 
absorbed and utilized by the host [81, 82]. Ninety percent of all SCFAs, including the 
majority of butyrate, produced are absorbed by the colonic microbiota [81]. Propionate 
is taken up by the human liver and acetate passes into host circulation freely [82]. 
Changes in Energy Balance- 
 Short chain fatty acid products are thought to play a role in regulation of 
satiety hormone release through the activation of free fatty acid receptors [7]. Free 
fatty acid receptors 2 and 3 (FFA2 and FFA3, respectively) found in human colonic 
cells, respond to the presence of particular SCFAs [83]. Acetate stimulates the FFA2 
receptor [84] and butyrate activates FFA3 [85]. Propionate acts as an agonist for both 
receptors. In mice, guinea pigs, and humans, enteroendocrine L cells that produce the 
satiety hormones peptide- YY (PYY) and Glucagon-Like Peptide-1 (GLP-1) are 
associated with greater expression of FFA2 and FFA3 [86-89]. Intravenous and rectal 
supplementation of SCFA increased release of GLP-1 and PYY in animal models [90].  
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 The alteration in GLP-1 and PYY resultant of increased SCFA concentrations 
with carbohydrate fermentation decreases insulin secretion and increases satiety [91]. 
Long term intake of fermentable carbohydrates increases colonic SCFA concentration. 
Increased SCFA in the colon is associated with higher L cell proliferation rates, 
possibly due to the increased expression of promoters for cell production [92, 93]. 
Understanding of the entire physiological role played by SCFAs and their interactions 
with enteroendocrine cells with respect to satiety hormones requires further research 
[7]. 
 An experimental randomized cross-over study of 19 human subjects (age 20-
35) compared voluntary food intake and serum levels of glucose, insulin, GLP-1, and 
ghrelin with different types and amounts of indigestible carbohydrate intake [8]. Peak 
blood glucose concentration levels after the subsequent breakfast meal were lower 
when subjects consumed the barley kernel wheat bread that contained more 
fermentable carbohydrate. Additionally, calorie intake at the following lunch was 
decreased by 15% in the barley kernel wheat bread compared to the whole wheat 
bread. Analysis showed a 16% decrease in plasma ghrelin when subjects consumed 
the barley kernel bread. Fasting blood glucose and insulin levels were not significantly 
different. The decrease in plasma ghrelin as a result of increased fermentable 
carbohydrate consumption could play a part in the reduced energy intake at 
subsequent meals during this study and may, after long term habitual consumption of 
fermentable carbohydrate, lead to improved energy balance. 
 In a study by Nilsson et al., [27] the effects of 50g indigestible carbohydrate 
(not resistant starch) at evening meals were examined in 15 healthy human subjects 
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age 22-32 years. Subjects consumed a standardized diet for two weeks prior to start of 
the study and then consumed an evening meal containing either barley kernel 
(containing 50g fermentable carbohydrate per meal) or white wheat bread. Bread 
made from barley kernel resulted in a greater decrease in post-breakfast glucose 
response (p<0.05), and lower glucose peaks (p<0.05) compared to white wheat bread. 
Bread made with barley kernels and higher amount of beta-glucans, a type of 
fermentable carbohydrate, resulted in a greater satiety ratings (p<0.05) and reduced 
inflammatory markers. Improved satiety as a result of increased fermentable 
carbohydrate consumption as seen in this study could lead to reduced energy intake 
and therefore improve energy balance over time. 
Changes in Blood Cholesterol- 
 While insoluble fibers have been shown to reduce blood cholesterol by 
inhibition of bile acid and cholesterol absorption as well as cholesterol synthesis [94, 
95], fermentable carbohydrates have been shown to more effectively decrease blood 
cholesterol levels [96]. It has been established that water soluble fibers bind to and 
interfere with resorption of bile acids [47], however the mechanistic role of SCFA 
byproducts on cholesterol lowering effects of fermentable carbohydrate are still being 
explored [7, 48-51]. 
 Rat cecal contents cultured with sugar beet fiber (SBF) in aerobic conditions to 
produce fermentation products, primarily SCFA, were fed to rats (80g fermentation 
product/ 100kg diet) [49]. SCFA and SBF containing diets both lowered plasma 
cholesterol significantly compared to a fiber-free control diet [49]. Additionally, rats 
fed a SCFA diet containing acetate had lower plasma cholesterol than the control diet, 
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whereas rats fed a SCFA diet without acetate did not differ in plasma cholesterol 
compared to the control. This study identifies acetate as the potential SCFA 
responsible for the cholesterol lowering effect of fermentable carbohydrates [49]. 
 Another study group fed male rats one of five diets: control, pectin containing, 
guar gum, gum arabic, or B-cyclodextrin [51]. Of the four diets containing 
fermentable carbohydrate, the guar gum and B-cyclodextrin diet fed rats exhibited 
lower triglyceride, LDL-C, and high density lipoprotein 1 cholesterol as well as 
decreased HMG-CoA reductase activity. Rats fed either guar gum or B-cyclodextrin 
also had significantly higher cecal propionate concentrations. In opposition to the 
previous study by Hara et al., conclusions from this study implicate propionate as a 
primary SCFA involved in reduction of blood cholesterol [51]. 
 A follow-up study using SCFA and SBF diets in rats also resulted in lower 
plasma total cholesterol in both diets compared to a fiber free control [48]. Greater in 
vitro cholesterol synthesis was observed in the SBF group compared to control while 
the SCFA diet resulted in lower synthesis rates. This is possibly due to the SBF diet 
stimulating increased bile acid excretion and SCFA inhibiting a downstream increase 
in hepatic cholesterol synthesis that accompanies increased bile acid excretion via 
regulation of HMG-CoA reductase regulation [48].  
 Previous studies corroborate the cholesterol lowering effect of fermentable 
carbohydrates. When fed a combination of guar gum, apple pectin, wheat bran, 
soybean fiber, and raw potato starch for 3 weeks, rats exhibited decreased blood 
cholesterol levels and triglycerides [50]. When fed a diet containing lard, oil, or 
dietary cholesterol in addition to fermentable carbohydrate, elevation of blood 
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cholesterol and triglycerides was not observed. All rats fed fermentable carbohydrate 
diets displayed increased cecal SCFA. Despite lower observed levels of HDL-C, 
plasma clearance of injected LDL-C was increased in the fermentable carbohydrate 
diet rats compared to a fiber free diet control group [50]. Additionally, liver 
triglycerides and cholesterol levels were lower and HMG-CoA reductase activity was 
higher in the fermentable carbohydrate fed rats [50]. 
 Other recent studies have shown changes in blood lipids with differing levels 
of OS.  A randomized trial consisting of 75 hypercholesterolemic human subjects 
receiving a pill containing 6 grams oat beta-glucan (an indigestible, fermentable 
carbohydrate) exhibited lower total cholesterol and significantly decreased LDL-C 
(p=0.026) after 6 weeks of supplementation.  
 One study in 12 men (average age 23 years) did not show significant change in 
blood lipid profiles after 3 weeks of 15g inulin, FOS or GOS supplementation [52]. 
This could potentially be due to the study population being apparently health and non-
diabetic or because baseline lipid values being healthy or low (although baseline 
values were not reported). 
Changes in Blood Pressure- 
 Hypertension has been associated with increased CVD morbidity and mortality 
risks [97]. Reductions of 2-5mmHg of  blood pressure have been shown to reduce 
stroke and CVD mortality risks [53]. The World Health Organization has 
recommended increasing dietary fiber in hypertensive individuals as a means to reduce 
risk of CVD [98]. Observational studies have shown an inverse relationship between 
fiber intake and hypertension [99, 100]. 
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 A meta-analysis of randomized controlled trials examined the effect of total 
fiber intake on blood pressure [44]. Older populations exhibited greater reductions in 
systolic blood pressure with fiber supplementation. Both systolic and diastolic blood 
pressures were lowered more in hypertensive populations than in normotensive. Sex 
and BMI did not affect these differences. Overall, researchers concluded that 
increasing fiber intake in populations consuming less than the recommendations may 
play a role in prevention of hypertension [44]. 
 While high fiber intakes have been associated with lower blood pressure, other 
factors including fruit and vegetable intake, sodium, potassium, magnesium, and 
calcium can also affect blood pressure [44, 101]. These factors could, therefore, 
confound potential associations of fiber with lower blood pressure [44]. 
 Fiber intake and cardiovascular events were monitored in more than 69,000 
male and female participants followed for over 10 years as a part of the Swedish 
Mammography Cohort and Cohort of Swedish Men [102]. Nutrient intake was 
measured using a food frequency questionnaire. After dividing participants into 
quintiles based on total dietary fiber intake, lower numbers of stroke and hemorrhage 
occurred in the highest quintile of fiber intake compared to those in the lowest 
quintile. Gender did not affect these results. Adjustments for intake of vitamin C, 
folate, B-carotene, magnesium, and potassium did not affect these results. Researchers 
noted that the observations of this study do differ with past research in which the 
inverse association of fiber intake and stroke were not persistent after adjustment for 
potassium and magnesium intakes [102, 103]. 
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 Insulin resistance and fasting glucose have been positively associated with risk 
of hypertension as part of the Insulin Resistance Atherosclerosis Study [104]. The 
prevalence of hypertension was also higher in those with type 2 diabetes [104]. For 
both diabetic and healthy subjects, the blood pressure lowering effects of water soluble 
fibers have been attributed to reductions in insulin resistance [105, 106]. Dietary fiber 
can impact insulin and vascular endothelial function which, in turn, alters blood 
pressure [42]. Arterial stiffness has been associated with increases in systolic and 
diastolic blood pressure [45, 107] and is a major risk factor for cardiovascular disease 
[46]. 
Changes in Glucose and Insulin- 
 Soluble fibers have a bulking effect that increases the viscosity of food passing 
through the gastrointestinal tract [108, 109]. This process slows gastric emptying, 
digestion, and absorption [108, 109]. The SCFA produced from colonic fermentation 
of fermentable carbohydrates can alter insulin sensitivity [110]. Recent research has 
examined the effects of these carbohydrates on postprandial blood glucose as well as 
long-term effects. 
 One experimental study of 88 human subjects (age 30-65) showed an alteration 
in dietary carbohydrate or fat changed the composition of gut microbiota [11]. 
Subjects were eligible if they were at risk for development of metabolic syndrome 
(two or more features of metabolic syndrome). After four weeks of high saturated fat/ 
high glycemic index (GI) diet, subjects were randomly assigned to diets including: 1) 
the control reference diet of high saturated fat/ high GI, 2) high monounsaturated fatty 
acid (MUFA)/high GI, 3) high MUFA/low GI, 4) high carbohydrate/high GI, or 5) 
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high carbohydrate/low GI. Diets 2, 3, 4, and 5 resulted in decreases in LDL-C 
compared to the initial four week diet (p<0.05). Increased consumption of non-starch 
polysaccharides was observed in the two low GI diets, (p<0.01). Fasting plasma 
glucose decreased in high carbohydrate diets (p<0.05 for both diets). Plasma insulin 
concentrations decreased in subjects consuming a high carbohydrate/ high GI diet 
(p<0.05). Increased carbohydrate in the diet resulted in a shift of intestinal microbiota 
to include a greater number of bifidobacteria. Overall, researchers determined that 
both type and quantity of dietary carbohydrate resulted in a shift in bacterial 
composition and activities in individuals at risk for metabolic syndrome [11]. 
Tools of Measuring Fermentable Carbohydrate 
 The Comprehensive Nutrition Assessment Questionnaire (CNAQ) is a 297-
item online questionnaire validated in 2010 for use in adults. The CNAQ evaluates 
intake of 52 nutritional indices designed to analyze dietary macronutrients, selected 
micronutrients, fermentable carbohydrate, starch, glycemic index, and glycemic load 
[28]. Completers of the CNAQ are prompted to evaluate their average intake of foods 
over a one-year duration. Potential responses include, but are not limited to “daily,” 
“weekly,” “monthly,” or “never or rarely”. Subjects are prompted to contemplate and 
identify quantities consumed of each food item on an annual basis with respect to 
abstract concepts such as dietary rotation of foods and seasonal items. The CNAQ 
survey page briefly instructs completers in documentation of quantities and 
conditional items such as those consumed only when in season. This FFQ may not be 
submitted for analysis with unanswered items.  
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 Responses to the CNAQ are processed by developers of the FFQ at Monash 
University in Australia using a food composition database [28]. The CNAQ survey 
generates feedback including the estimated daily intake of total and individual mono- 
and disaccharides (g), oligosaccharides (g), fructans (g), galactooligosaccharides (g), 
raffinose (g), stachyose (g), sorbitol (g), mannitol (g), glycemic load, glycemic index, 
total energy (kJ), macronutrients (g), vitamins and minerals (mg), dietary fiber (g), and 
cholesterol (mg). Compared to three day diet records, the CNAQ validation study 
indicated that nutrients were overestimated by an average of 140% (with a range of 
95-249%). 
 The CNAQ’s ability to measure OS and OS subtypes in addition to 
monosaccharides, disaccharides, and polyols allows researchers to estimate 
fermentable carbohydrate intakes in these categories. Other dietary recall and analysis 
programs may contain more food items compared to the 297 items addressed in the 
CNAQ but do not quantify all types of fermentable carbohydrates. For example, the 
Nutrition Data System for Research contains over 23,000 foods and quantifies 
monosaccharides, disaccharides, polyols, and fibers, some of which can be fermented, 
but does not quantify oligosaccharides or their subtypes [111]. Comparatively, the 
CNAQ is a tool to estimate present intake of fermentable carbohydrate and particular 
subtypes. 
 The CNAQ was validated in Australia for quantification of FODMAP 
carbohydrates [28]. It has not been used for applied research purposes in the US to 
date. Additionally, the researchers responsible for validation of the CNAQ stated that 
46 
 
the 297 items required to accurately assess FODMAP intake were excessive compared 
to other FFQs which could lead to loss of concentration and accuracy [28].  
Implications of Fermentable Carbohydrates for Health 
 As discussed previously, indigestible fermentable carbohydrates and the 
byproducts of fermentation have multiple potential health benefits related to obesity, 
glucose regulation, blood pressure, and blood cholesterol. Obesity, poor glucose 
regulation, hypertension, and dyslipidemia are risk factors related to metabolic 
syndrome, which may be improved by increased consumption of fermentable 
carbohydrate. According to the American Heart Association [112], criteria for clinical 
diagnosis of metabolic syndrome includes any 3 of five factors:  
1. Obesity: waist circumference >102cm in males or >88cm in females 
2. Blood triglycerides > 150mg/dL 
3. High density lipoprotein (HDL) cholesterol < 40mg/dL in males or < 50mg/dL in 
females 
4. Blood pressure > 130/85mmHg 
5. Fasting glucose >100mg/dL 
 Presence of metabolic syndrome can increase risk for the development of 
CVD. Decreasing blood LDL-C is also a major focus of therapy in patients with CVD 
and those at cardiovascular risk [68]. Cardiovascular disease is currently the leading 
cause of death in the US with 1 in 3 Americans dying of heart disease or stroke [113]. 
From 2007 to 2010 approximately 7.3% of male adolescents (age 12-19 years) and 
7.6% of female adolescents had high blood LDL-C (>130mg/dL) [114]. Some 
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research subjects have decreased blood LDL-C after the inclusion of fermentable 
carbohydrate, such as dietary oat-bran, or other fibers [11, 68, 76].   
 There is evidence to suggest that fermentable carbohydrates have beneficial 
health effects including reduction of factors associated with hyperlipidemia as well as 
body weight and insulin resistance [8, 12, 27]. Current studies focus on the 
implications of poorly digested, fermentable carbohydrates relating to decreasing 
adverse symptoms in subjects with irritable bowel syndrome or intestinal bowel 
disease [14, 19, 24, 25] while others promote the prebiotic effects of these indigestible 
molecules [20, 26]. However, these are mostly short-term studies. There is no research 
regarding average intake of total indigestible, fermentable carbohydrates in the US 
young adult population. Furthermore, intakes of subclasses of such carbohydrates, 
including the short-chain polyols and the longer-chain oligosaccharides, have not been 
explored, especially with regard to their differential impacts on health parameters.  
Need for Examining Fermentable Carbohydrate Intake 
 Indigestible, fermentable carbohydrates display prebiotic effects and may 
influence obesity, glucose regulation, blood pressure, and blood cholesterol. Resistant 
starch is the most quantitatively important fermentable carbohydrate, however this 
carbohydrate type does not selectively promote the growth of beneficial bacteria [20]. 
Furthermore, it cannot yet be quantified in free-living individuals due to the various 
internal and external factors that affect structure and digestibility [57]. Particular 
fermentable carbohydrates including oligosaccharides and some di- and 
monosaccharides, such as polyols, are consumed in smaller amounts but may elicit 
some health benefits. A review by Gibson [20] predicts that  4-8g of these 
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carbohydrates may be needed to see significant impact, however habitual intake in the 
US population has not been quantified. As habitual intakes of fermentable 
carbohydrates and their subclasses have not been explored in the general US 
population, observation of habitual intake is necessary to further understand their 
potential metabolic effects. 
 
  
49 
 
APPENDIX 2: CONSENT FORM 
 
 
  
50 
 
 
   
51 
 
APPENDIX 3: NUTRITION ASSESSMENT STUDY SURVEY 
 
 
52 
 
   
53 
 
 
 
  
54 
 
APPENDIX 4: CNAQ TRANSLATION SHEET 
 
 
  
55 
 
BIBLIOGRAPHY 
1. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease 
burden associated with overweight and obesity. JAMA. 1999;282(16):1523-9.  
2. Yang L, Colditz GA. Prevalence of Overweight and Obesity in the United States, 
2007-2012. JAMA Intern Med. 2015. doi:10.1001/jamainternmed.2015.2405. 
3. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C, American Heart 
A et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and 
Blood Institute/American Heart Association conference on scientific issues related to 
definition. Circulation. 2004;109(3):433-8. 
doi:10.1161/01.CIR.0000111245.75752.C6. 
4. Morrell JS, Lofgren IE, Burke JD, Reilly RA. Metabolic Syndrome, Obesity, and 
Related Risk Factors Among College Men and Women. J Am Coll Health. 
2012;60(1):82-9. doi:10.1080/07448481.2011.582208. 
5. McGuire S. Institute of Medicine. 2012. Accelerating progress in obesity 
prevention: solving the weight of the nation. Washington, DC: the National 
Academies Press. Adv Nutr. 2012;3(5):708-9. doi:10.3945/an.112.002733. 
6. Spencer L. Results of a heart disease risk-factor screening among traditional college 
students. J Am Coll Health. 2002;50(6):291-6.  
7. Kaji I, Karaki S, Kuwahara A. Short-chain fatty acid receptor and its contribution to 
glucagon-like peptide-1 release. Digestion. 2014;89(1):31-6. doi:10.1159/000356211. 
8. Johansson EV, Nilsson AC, Ostman EM, Bjorck IM. Effects of indigestible 
carbohydrates in barley on glucose metabolism, appetite and voluntary food intake 
over 16 h in healthy adults. Nutr J. 2013;12:46. doi:10.1186/1475-2891-12-46. 
9. Cani PD, Delzenne NM, Amar J, Burcelin R. Role of gut microflora in the 
development of obesity and insulin resistance following high-fat diet feeding. Pathol 
Biol. 2008;56(5):305-9. doi:10.1016/j.patbio.2007.09.008. 
10. Vulevic J, Juric A, Tzortzis G, Gibson GR. A mixture of trans-
galactooligosaccharides reduces markers of metabolic syndrome and modulates the 
fecal microbiota and immune function of overweight adults. J Nutr. 2013;143(3):324-
31. doi:10.3945/jn.112.166132. 
11. Fava F, Gitau R, Griffin BA, Gibson GR, Tuohy KM, Lovegrove JA. The type and 
quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty 
acid excretion in a metabolic syndrome 'at-risk' population. Int J Obes. 
2013;37(2):216-23. doi:10.1038/ijo.2012.33. 
12. Delzenne NM, Kok NN. Biochemical basis of oligofructose-induced 
hypolipidemia in animal models. J Nutr. 1999;129(7 Suppl):1467S-70S.  
56 
 
13. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM et al. 
Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced 
diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 
2007;50(11):2374-83. doi:10.1007/s00125-007-0791-0. 
14. de Roest RH, Dobbs BR, Chapman BA, Batman B, O'Brien LA, Leeper JA et al. 
The low FODMAP diet improves gastrointestinal symptoms in patients with irritable 
bowel syndrome: a prospective study. Int J Clin Pract. 2013;67(9):895-903. 
doi:10.1111/ijcp.12128. 
15. Ito M, Deguchi Y, Miyamori A, Matsumoto K, Kikuchi H, Matsumoto K et al. 
Effects of Administration of Galactooligosaccharides on the Human Faecal 
Microflora, Stool Weight and Abdominal Sensation. Microb Ecol Health Dis. 
1990;3(6):285-92. doi:doi:10.3109/08910609009140251. 
16. Langlands SJ, Hopkins MJ, Coleman N, Cummings JH. Prebiotic carbohydrates 
modify the mucosa associated microflora of the human large bowel. Gut. 
2004;53(11):1610-6. doi:10.1136/gut.2003.037580. 
17. Tuohy KM, Kolida S, Lustenberger AM, Gibson GR. The prebiotic effects of 
biscuits containing partially hydrolysed guar gum and fructo-oligosaccharides--a 
human volunteer study. Brit J Nutr. 2001;86(3):341-8.  
18. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: 
introducing the concept of prebiotics. J Nutr. 1995;125(6):1401-12.  
19. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional 
gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol. 
2010;25(2):252-8. doi:10.1111/j.1440-1746.2009.06149.x. 
20. Gibson GR. Fibre and effects on Probiotics (the Prebiotic Concept). J Clin Nutr. 
2004(1):25-31.  
21. Cummings JH, Macfarlane GT. The control and consequences of bacterial 
fermentation in the human colon. J Appl Bacteriol. 1991;70(6):443-59.  
22. Gibson GR, Wang X. Enrichment of bifidobacteria from human gut contents by 
oligofructose using continuous culture. FEMS microbiology letters. 1994;118(1-
2):121-7.  
23. Gopal PK, Sullivan PA, Smart JB. Utilisation of galacto-oligosaccharides as 
selective substrates for growth by lactic acid bacteria including Bifidobacterium lactis 
DR10 and Lactobacillus rhamnosus DR20. Int Dairy J. 2001;11(1-2):19-25. doi:Doi 
10.1016/S0958-6946(01)00026-7. 
24. Leenen CH, Dieleman LA. Inulin and oligofructose in chronic inflammatory 
bowel disease. J Nutr. 2007;137(11 Suppl):2572S-5S.  
57 
 
25. Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR et al. 
Manipulation of dietary short chain carbohydrates alters the pattern of gas production 
and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 
2010;25(8):1366-73. doi:10.1111/j.1440-1746.2010.06370.x. 
26. Foxx-Orenstein A. Manipulation of the Gut Microbiota as a Novel Treatment 
Strategy for Gastrointestinal Disorders. Am J Gastroenterol Suppl. 2012(1):41-6.  
27. Nilsson AC, Ostman EM, Holst JJ, Bjorck IM. Including indigestible 
carbohydrates in the evening meal of healthy subjects improves glucose tolerance, 
lowers inflammatory markers, and increases satiety after a subsequent standardized 
breakfast. J Nutr. 2008;138(4):732-9.  
28. Barrett JS, Gibson PR. Development and validation of a comprehensive semi-
quantitative food frequency questionnaire that includes FODMAP intake and glycemic 
index. J Am Diet Assoc. 2010;110(10):1469-76. doi:10.1016/j.jada.2010.07.011. 
29. McCrory MA, Mole PA, Gomez TD, Dewey KG, Bernauer EM. Body 
composition by air-displacement plethysmography by using predicted and measured 
thoracic gas volumes. J Appl Physiol. 1998;84(4):1475-9.  
30. Wolever TM, Tosh SM, Gibbs AL, Brand-Miller J, Duncan AM, Hart V et al. 
Physicochemical properties of oat beta-glucan influence its ability to reduce serum 
LDL cholesterol in humans: a randomized clinical trial. Am J Clin Nutr. 
2010;92(4):723-32. doi:10.3945/ajcn.2010.29174. 
31. George GC, Milani TJ, Hanss-Nuss H, Kim M, Freeland-Graves JH. Development 
and validation of a semi-quantitative food frequency questionnaire for young adult 
women in the southwestern United States. Nutr Res. 2004;24(1):29-43. doi:Doi 
10.1016/S0271-5317(03)00220-3. 
32. Cani PD, Joly E, Horsmans Y, Delzenne NM. Oligofructose promotes satiety in 
healthy human: a pilot study. Eur J Clin Nutr. 2006;60(5):567-72. 
doi:10.1038/sj.ejcn.1602350. 
33. Ebel B, Lemetais G, Beney L, Cachon R, Sokol H, Langella P et al. Impact of 
probiotics on risk factors for cardiovascular diseases. A review. Crit Rev Food Sci 
Nutr. 2014;54(2):175-89. doi:10.1080/10408398.2011.579361. 
34. Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a 
systematic review and meta-analysis of randomized, controlled trials. Hypertension. 
2014;64(4):897-903. doi:10.1161/HYPERTENSIONAHA.114.03469. 
35. Aihara K, Kajimoto O, Hirata H, Takahashi R, Nakamura Y. Effect of powdered 
fermented milk with Lactobacillus helveticus on subjects with high-normal blood 
pressure or mild hypertension. J Am Coll Nutr. 2005;24(4):257-65.  
58 
 
36. Seppo L, Jauhiainen T, Poussa T, Korpela R. A fermented milk high in bioactive 
peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin 
Nutr. 2003;77(2):326-30.  
37. Donkor ON, Henriksson A, Singh TK, Vasiljevic T, Shah NP. ACE-inhibitory 
activity of probiotic yoghurt. Int Dairy J. 2007;17(11):1321-31. 
doi:10.1016/j.idairyj.2007.02.009. 
38. Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S, Takano T. 
Purification and characterization of angiotensin I-converting enzyme inhibitors from 
sour milk. J Dairy Sci. 1995;78(4):777-83. doi:10.3168/jds.S0022-0302(95)76689-9. 
39. Ong L, Shah NP. Release and identification of angiotensin-converting enzyme-
inhibitory peptides as influenced by ripening temperatures and probiotic adjuncts in 
Cheddar cheeses. Lwt Food Sci Technol. 2008;41(9):1555-66. 
doi:10.1016/j.lwt.2007.11.026. 
40. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key 
therapeutic strategy to reduce renal and cardiovascular events in patients with 
diabetes. J Hypertens. 2006;24(1):11-25.  
41. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-
receptor blockade on the response to angiotensin-converting-enzyme inhibitor in 
normotensive and hypertensive subjects. N Engl J Med. 1998;339(18):1285-92. 
doi:10.1056/NEJM199810293391804. 
42. Bessesen DH. The role of carbohydrates in insulin resistance. J Nutr. 
2001;131(10):2782S-6S.  
43. Pal S, Khossousi A, Binns C, Dhaliwal S, Radavelli-Bagatini S. The effects of 12-
week psyllium fibre supplementation or healthy diet on blood pressure and arterial 
stiffness in overweight and obese individuals. Brit J Nutr. 2012;107(5):725-34. 
doi:Doi 10.1017/S0007114511003497. 
44. Streppel MT, Arends LR, van 't Veer P, Grobbee DE, Geleijnse JM. Dietary fiber 
and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch 
Intern Med. 2005;165(2):150-6. doi:10.1001/archinte.165.2.150. 
45. Safar ME. Systolic blood pressure, pulse pressure and arterial stiffness as 
cardiovascular risk factors. Curr Opin Nephrol Hypertens. 2001;10(2):257-61.  
46. Qureshi G, Brown R, Salciccioli L, Qureshi M, Rizvi S, Farhan S et al. 
Relationship between aortic atherosclerosis and non-invasive measures of arterial 
stiffness. Atherosclerosis. 2007;195(2):e190-4. 
doi:10.1016/j.atherosclerosis.2007.06.021. 
47. Anderson JW. Physiological and metabolic effects of dietary fiber. Fed Proc. 
1985;44(14):2902-6.  
59 
 
48. Hara H, Haga S, Aoyama Y, Kiriyama S. Short-chain fatty acids suppress 
cholesterol synthesis in rat liver and intestine. J Nutr. 1999;129(5):942-8.  
49. Hara H, Haga S, Kasai T, Kiriyama S. Fermentation products of sugar-beet fiber 
by cecal bacteria lower plasma cholesterol concentration in rats. J Nutr. 
1998;128(4):688-93.  
50. Mazur A, Remesy C, Gueux E, Levrat MA, Demigne C. Effects of diets rich in 
fermentable carbohydrates on plasma lipoprotein levels and on lipoprotein catabolism 
in rats. J Nutr. 1990;120(9):1037-45.  
51. Moundras C, Behr SR, Demigne C, Mazur A, Remesy C. Fermentable 
polysaccharides that enhance fecal bile acid excretion lower plasma cholesterol and 
apolipoprotein E-rich HDL in rats. J Nutr. 1994;124(11):2179-88.  
52. van Dokkum W, Wezendonk B, Srikumar TS, van den Heuvel EG. Effect of 
nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations 
and glucose absorption in young healthy male subjects. Eur J Clin Nutr. 1999;53(1):1-
7.  
53. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM et al. Dietary 
approaches to prevent and treat hypertension: a scientific statement from the American 
Heart Association. Hypertension. 2006;47(2):296-308. 
doi:10.1161/01.HYP.0000202568.01167.B6. 
54. van Loo J, Coussement P, de Leenheer L, Hoebregs H, Smits G. On the presence 
of inulin and oligofructose as natural ingredients in the western diet. Crit Rev Food Sci 
Nutr. 1995;35(6):525-52. doi:10.1080/10408399509527714. 
55. Niness KR. Inulin and oligofructose: What are they? J Nutr. 1999;129(7):1402s-
6s.  
56. Sako T, Matsumoto K, Tanaka R. Recent progress on research and applications of 
non-digestible galacto-oligosaccharides. Int Dairy J. 1999;9(1):69-80. 
doi:http://dx.doi.org/10.1016/S0958-6946(99)00046-1. 
57. Raigond P, Ezekiel R, Raigond B. Resistant starch in food: a review. J Sci Food 
Agric. 2015;95(10):1968-78. doi:10.1002/jsfa.6966. 
58. Perrin S, Warchol M, Grill JP, Schneider F. Fermentations of fructo-
oligosaccharides and their components by Bifidobacterium infantis ATCC 15697 on 
batch culture in semi-synthetic medium. J Appl Microbiol. 2001;90(6):859-65. 
doi:DOI 10.1046/j.1365-2672.2001.01317.x. 
59. Probert HM, Apajalahti JH, Rautonen N, Stowell J, Gibson GR. Polydextrose, 
lactitol, and fructo-oligosaccharide fermentation by colonic bacteria in a three-stage 
continuous culture system. Appl Environ Microbiol. 2004;70(8):4505-11. 
doi:10.1128/AEM.70.8.4505-4511.2004. 
60 
 
60. Torres DPM, Gonçalves MdPF, Teixeira JA, Rodrigues LR. Galacto-
Oligosaccharides: Production, Properties, Applications, and Significance as Prebiotics. 
Compr Rev Food Sci Food Saf. 2010;9(5):438-54. doi:10.1111/j.1541-
4337.2010.00119.x. 
61. Fedewa A, Rao SS. Dietary fructose intolerance, fructan intolerance and 
FODMAPs. Curr Gastroenterol Rep. 2014;16(1):370. doi:10.1007/s11894-013-0370-
0. 
62. Nilsson KGI. Enzymatic synthesis of oligosaccharides. Trends Biotechnol. 
1988;6(10):256-64. doi:http://dx.doi.org/10.1016/0167-7799(88)90058-3. 
63. Biesiekierski JR, Rosella O, Rose R, Liels K, Barrett JS, Shepherd SJ et al. 
Quantification of fructans, galacto-oligosacharides and other short-chain 
carbohydrates in processed grains and cereals. J Hum Nur Diet. 2011;24(2):154-76. 
doi:10.1111/j.1365-277X.2010.01139.x. 
64. Jovanovic-Malinovska R, Kuzmanova S, Winkelhausen E. Oligosaccharide Profile 
in Fruits and Vegetables as Sources of Prebiotics and Functional Foods. Int J Food 
Prop. 2014;17(5):949-65. doi:Doi 10.1080/10942912.2012.680221. 
65. Imamura L, Hisamitsu K, Kobashi K. Purification and characterization of beta-
fructofuranosidase from Bifidobacterium infantis. Biol Pharm Bull. 1994;17(5):596-
602.  
66. Grabitske HA, Slavin JL. Low-digestible carbohydrates in practice. J Am Diet 
Assoc. 2008;108(10):1677-81. doi:10.1016/j.jada.2008.07.010. 
67. Nabors LO. Regulatory status of alternative sweeteners. Food Technol. 
2007;61(5):24-+.  
68. Mahan LK, Escott-Stump S, Raymond JL, Krause MV. Krause's food & the 
nutrition care process. 13th ed. St. Louis, Mo.: Elsevier/Saunders; 2012. 
69. Stipanuk MH, Caudill MA. Biochemical, physiological, and molecular aspects of 
human nutrition. 3rd ed. St. Louis, Mo.: Elsevier/Saunders; 2013. 
70. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB. Dietary modulation 
of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev. 
2004;17(2):259-75. doi:10.1079/NRR200479. 
71. Bosscher D, Breynaert A, Pieters L, Hermans N. Food-based strategies to 
modulate the composition of the intestinal microbiota and their associated health 
effects. J Physiol Pharmacol. 2009;60 Suppl 6:5-11.  
72. Gibson GR. Dietary modulation of the human gut microflora using prebiotics. Brit 
J Nutr. 1998;80(4):S209-12.  
61 
 
73. Sekine K, Toida T, Saito M, Kuboyama M, Kawashima T, Hashimoto Y. A new 
morphologically characterized cell wall preparation (whole peptidoglycan) from 
Bifidobacterium infantis with a higher efficacy on the regression of an established 
tumor in mice. Cancer Res. 1985;45(3):1300-7.  
74. Smith P, Siddharth J, Pearson R, Holway N, Shaxted M, Butler M et al. Host 
genetics and environmental factors regulate ecological succession of the mouse colon 
tissue-associated microbiota. PLoS One. 2012;7(1):e30273. 
doi:10.1371/journal.pone.0030273. 
75. Younes H, Demigne C, Remesy C. Acidic fermentation in the caecum increases 
absorption of calcium and magnesium in the large intestine of the rat. Brit J Nutr. 
1996;75(2):301-14.  
76. Queenan KM, Stewart ML, Smith KN, Thomas W, Fulcher RG, Slavin JL. 
Concentrated oat beta-glucan, a fermentable fiber, lowers serum cholesterol in 
hypercholesterolemic adults in a randomized controlled trial. Nutr J. 2007;6:6. 
doi:10.1186/1475-2891-6-6. 
77. Campbell JM, Fahey GC, Jr., Wolf BW. Selected indigestible oligosaccharides 
affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in 
rats. J Nutr. 1997;127(1):130-6.  
78. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: 
roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81(3):1031-
64.  
79. Burcelin R. Regulation of metabolism: a cross talk between gut microbiota and its 
human host. Physiology (Bethesda). 2012;27(5):300-7. 
doi:10.1152/physiol.00023.2012. 
80. Hoverstad T, Fausa O, Bjorneklett A, Bohmer T. Short-chain fatty acids in the 
normal human feces. Scand  J Gastroenterol. 1984;19(3):375-81.  
81. Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic 
mucosa in man. Gut. 1980;21(9):793-8.  
82. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain 
fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 
1987;28(10):1221-7.  
83. Stoddart LA, Smith NJ, Milligan G. International Union of Pharmacology. LXXI. 
Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological 
functions. Pharmacol Rev. 2008;60(4):405-17. doi:10.1124/pr.108.00802. 
84. Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free fatty acid 
receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. 
Biochem Biophys Res Commun. 2003;303(4):1047-52.  
62 
 
85. Hudson BD, Tikhonova IG, Pandey SK, Ulven T, Milligan G. Extracellular ionic 
locks determine variation in constitutive activity and ligand potency between species 
orthologs of the free fatty acid receptors FFA2 and FFA3. J Biol Chem. 
2012;287(49):41195-209. doi:10.1074/jbc.M112.396259. 
86. Karaki S, Kuwahara A. Propionate-induced epithelial K(+) and Cl(-)/HCO3(-) 
secretion and free fatty acid receptor 2 (FFA2, GPR43) expression in the guinea pig 
distal colon. Pflugers Arch. 2011;461(1):141-52. doi:10.1007/s00424-010-0889-y. 
87. Karaki S, Mitsui R, Hayashi H, Kato I, Sugiya H, Iwanaga T et al. Short-chain 
fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast 
cells in rat intestine. Cell Tissue Res. 2006;324(3):353-60. doi:10.1007/s00441-005-
0140-x. 
88. Karaki S, Tazoe H, Hayashi H, Kashiwabara H, Tooyama K, Suzuki Y et al. 
Expression of the short-chain fatty acid receptor, GPR43, in the human colon. J Mol 
Histol. 2008;39(2):135-42. doi:10.1007/s10735-007-9145-y. 
89. Tazoe H, Otomo Y, Karaki S, Kato I, Fukami Y, Terasaki M et al. Expression of 
short-chain fatty acid receptor GPR41 in the human colon. Biomed Res. 
2009;30(3):149-56.  
90. Freeland KR, Wolever TM. Acute effects of intravenous and rectal acetate on 
glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-
alpha. Brit J Nutr. 2010;103(3):460-6. doi:10.1017/S0007114509991863. 
91. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E et al. 
Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-
coupled receptor FFAR2. Diabetes. 2012;61(2):364-71. doi:10.2337/db11-1019. 
92. Cani PD, Hoste S, Guiot Y, Delzenne NM. Dietary non-digestible carbohydrates 
promote L-cell differentiation in the proximal colon of rats. Brit J Nutr. 
2007;98(1):32-7. doi:10.1017/S0007114507691648. 
93. Kaji I, Karaki S, Tanaka R, Kuwahara A. Density distribution of free fatty acid 
receptor 2 (FFA2)-expressing and GLP-1-producing enteroendocrine L cells in human 
and rat lower intestine, and increased cell numbers after ingestion of fructo-
oligosaccharide. J Mol Histol. 2011;42(1):27-38. doi:10.1007/s10735-010-9304-4. 
94. Carr TP, Gallaher DD, Yang CH, Hassel CA. Increased intestinal contents 
viscosity reduces cholesterol absorption efficiency in hamsters fed hydroxypropyl 
methylcellulose. J Nutr. 1996;126(5):1463-9.  
95. Gallaher DD, Hassel CA, Lee KJ, Gallaher CM. Viscosity and fermentability as 
attributes of dietary fiber responsible for the hypocholesterolemic effect in hamsters. J 
Nutr. 1993;123(2):244-52.  
63 
 
96. Younes H, Levrat MA, Demigne C, Remesy C. Resistant starch is more effective 
than cholestyramine as a lipid-lowering agent in the rat. Lipids. 1995;30(9):847-53.  
97. Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P et al. Clustering of 
cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null 
mice. Swiss Med Wkly. 2003;133(25-26):360-3. doi:2003/25/smw-10239. 
98. Diet, nutrition and the prevention of chronic diseases. World Health Organ Tech 
Rep Ser. 2003;916:i-viii, 1-149, backcover.  
99. Burke V, Hodgson JM, Beilin LJ, Giangiulioi N, Rogers P, Puddey IB. Dietary 
protein and soluble fiber reduce ambulatory blood pressure in treated hypertensives. 
Hypertension. 2001;38(4):821-6.  
100. Galisteo M, Duarte J, Zarzuelo A. Effects of dietary fibers on disturbances 
clustered in the metabolic syndrome. J Nutr Biochem. 2008;19(2):71-84. 
doi:10.1016/j.jnutbio.2007.02.009. 
101. Alonso A, Beunza JJ, Bes-Rastrollo M, Pajares RM, Martinez-Gonzalez MA. 
Vegetable protein and fiber from cereal are inversely associated with the risk of 
hypertension in a Spanish cohort. Arch Med Res. 2006;37(6):778-86. 
doi:10.1016/j.arcmed.2006.01.007. 
102. Larsson SC, Wolk A. Dietary fiber intake is inversely associated with stroke 
incidence in healthy Swedish adults. J Nutr. 2014;144(12):1952-5. 
doi:10.3945/jn.114.200634. 
103. Ascherio A, Rimm EB, Hernan MA, Giovannucci EL, Kawachi I, Stampfer MJ et 
al. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US 
men. Circulation. 1998;98(12):1198-204.  
104. Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S et al. Insulin 
resistance and hypertension: the Insulin Resistance Atherosclerosis study. 
Hypertension. 2004;43(6):1324-31. doi:10.1161/01.HYP.0000128019.19363.f9. 
105. Anderson JW, Zeigler JA, Deakins DA, Floore TL, Dillon DW, Wood CL et al. 
Metabolic effects of high-carbohydrate, high-fiber diets for insulin-dependent diabetic 
individuals. Am J Clin Nutr. 1991;54(5):936-43.  
106. Fukagawa NK, Anderson JW, Hageman G, Young VR, Minaker KL. High-
carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young 
and old adults. Am J Clin Nutr. 1990;52(3):524-8.  
107. Tomiyama H, Hashimoto H, Hirayama Y, Yambe M, Yamada J, Koji Y et al. 
Synergistic acceleration of arterial stiffening in the presence of raised blood pressure 
and raised plasma glucose. Hypertension. 2006;47(2):180-8. 
doi:10.1161/01.HYP.0000198539.34501.1a. 
64 
 
108. Koh-Banerjee P, Franz M, Sampson L, Liu S, Jacobs DR, Jr., Spiegelman D et al. 
Changes in whole-grain, bran, and cereal fiber consumption in relation to 8-y weight 
gain among men. Am J Clin Nutr. 2004;80(5):1237-45.  
109. Weickert MO, Mohlig M, Schofl C, Arafat AM, Otto B, Viehoff H et al. Cereal 
fiber improves whole-body insulin sensitivity in overweight and obese women. 
Diabetes Care. 2006;29(4):775-80.  
110. Pereira MA, Ludwig DS. Dietary fiber and body-weight regulation. Observations 
and mechanisms. Pediatr Clin North Am. 2001;48(4):969-80.  
111. Dennis B, Ernst N, Hjortland M, Tillotson J, Grambsch V. The NHLBI nutrition 
data system. J Am Diet Assoc. 1980;77(6):641-7.  
112. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et 
al. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the 
International Diabetes Federation Task Force on Epidemiology and Prevention; 
National Heart, Lung, and Blood Institute; American Heart Association; World Heart 
Federation; International Atherosclerosis Society; and International Association for 
the Study of Obesity. Circulation. 2009;120(16):1640-5. doi:Doi 
10.1161/Circulationaha.109.192644. 
113. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al. 
Heart disease and stroke statistics--2015 update: a report from the American Heart 
Association. Circulation. 2015;131(4):e29-322. doi:10.1161/CIR.0000000000000152. 
114. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al. Heart 
disease and stroke statistics--2014 update: a report from the American Heart 
Association. Circulation. 2014;129(3):e28-e292. 
doi:10.1161/01.cir.0000441139.02102.80. 
 
 
